Lansoprazole (Synonyms: AG-1749)

Cat. No.: HY-13662 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).

For research use only. We do not sell to patients.

Lansoprazole Chemical Structure

CAS No. : 103577-45-3

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solution
10 mM * 1 mL in DMSO	USD 61	In-stock	Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL ready for reconstitution	USD 61	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	USD 55	In-stock	Estimated Time of Arrival: December 31
1 g	USD 79	In-stock	Estimated Time of Arrival: December 31
5 g	USD 343	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Lansoprazole:

(R)-Lansoprazole In-stock
Lansoprazole-d₄ In-stock

Featured Recommendations

•Related Screening Libraries:

View All Phospholipase Isoform Specific Products:

View All Isoforms

Phospholipase A PLD

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Lansoprazole from 0.3 to 3 μM inhibits gastric acid formation in a concentration-dependent manner (IC₅₀ of 0.76 μM)^[4].
Lansoprazole (30-300 μM) both induced concentration-dependent, reversible and reproducible relaxations of arteries^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lansoprazole (20-40 mg/kg) treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations^[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced increase in AChE activity^[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced rise in brain MPO level^[3].
Further HFD mice treated with lansoprazole (20 mg/kg and 40 mg/kg, p.o.) shows a marked decrease in the body weight in comparison to the control animals^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss albino mice (20–25 g) of either sex^[3].
Dosage:	20 mg/kg, 40 mg/kg.
Administration:	PO, started after second dose of STZ and then subjected to MWM test. Continued (30 min before) during the acquisition trial conducted from day 1 to day 4.
Result:	Significantly attenuated the day 4 rise in ELT and decreased in day 5 TSTQ in the STZ as well as HFD treated mice in a dose dependent manner.

Clinical Trial

Molecular Weight

369.36

Appearance

Solid

Formula

C₁₆H₁₄F₃N₃O₂S

CAS No.

103577-45-3

SMILES

O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (270.74 mM; Need ultrasonic)

H₂O : 0.1 mg/mL (0.27 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7074 mL	13.5369 mL	27.0739 mL
5 mM	0.5415 mL	2.7074 mL	5.4148 mL
10 mM	0.2707 mL	1.3537 mL	2.7074 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

*All of the co-solvents are available by MCE.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (247 KB) HNMR (269 KB)

Handling Instructions (2659 KB)

References

[1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5. [Content Brief]

[2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [Content Brief]

[3]. Rupinder K Sodhi, et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487. [Content Brief]

[4]. Jun Matsukawa, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51. [Content Brief]

[5]. Erdinc Naseri, et al. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol. 2006 Feb 15;531(1-3):226-31. [Content Brief]

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Keywords:

Lansoprazole103577-45-3AG-1749AG1749AG 1749Proton PumpBacterialPhospholipaseSTZHFDgastricacidexosomeN-SMaseELTTSTQInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email address *

Phone number *

Organization name *

Department *

Requested quantity *

Country or Region *

Remarks